Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.01.2024 | Case report

Colchicine/nonsteroidal anti inflammatories/Pembrolizumab

Myopericarditis and treatment failure

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Hamandi M, et al. Rilonacept for Refractory Pericarditis Following Immune Checkpoint Inhibitor Therapy: A Case Report. Circulation 148 (Suppl. 1): abstr. 15265, Nov 2023. Available from: URL: https://dx.doi.org/10.1161/circ.148.suppl_1.15265 [abstract] Hamandi M, et al. Rilonacept for Refractory Pericarditis Following Immune Checkpoint Inhibitor Therapy: A Case Report. Circulation 148 (Suppl. 1): abstr. 15265, Nov 2023. Available from: URL: https://dx.doi.org/10.1161/circ.148.suppl_1.15265 [abstract]
Metadaten
Titel
Colchicine/nonsteroidal anti inflammatories/Pembrolizumab
Myopericarditis and treatment failure
Publikationsdatum
01.01.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-52228-1

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe